UNSPSC 51283923: Sulfametrole

This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H10N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5AK41IPQG, chemically known as 4-amino-n-(5-methoxy-2,1,3-thiadiazol-4-yl)benzolsulfonamid but generally known as sulfametrole, which bears US NIH Compound Identifier 64939. European Medicines Agency schedules Sulfametrole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10715MIG.

UNSPSC 51283923 Sulfametrole, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally designates a specific antimicrobial pharmaceutical agent, yet the recent opportunities posted under this code do not include sulfametrole procurement; instead, they span naloxone distribution systems, pharmacy benefit program restructuring, broad medical and first aid supply acquisition, and multi-source generic pharmaceutical contracting. The mismatch between the code's narrow pharmaceutical designation and the actual buying activity suggests either tagging inconsistency or use of the code as a catchall for health-service pharmaceutical procurement. When state and local solicitations do target specific pharmaceuticals or medical supplies, they typically reflect emergency response, public health, or managed care objectives rather than single-agent procurement.

The recent opportunities show activity across Florida county health systems (Seminole County's naloxone and drug deactivation systems IFB, posted June 30, 2026), Texas state health agencies (HHS Commission RFI on direct-to-manufacturer pharmacy programs, posted April 3, 2026), municipal fire and emergency services (City of Tampa medical and first aid supplies IFB, posted March 25, 2026, with an estimated contract value of $700,000.00 and a certified Small Local Business Enterprise set-aside), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance RFP for generic pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026). The geographic spread spans Florida, Texas, and the upper Midwest, with the Tampa opportunity carrying explicit SLBE preference and the MMCAP procurement leveraging cooperative purchasing with authorized wholesalers. Given the code's specificity and the absence of sulfametrole-specific opportunities in the recent record, firms pursuing state and local pharmaceutical or medical supply contracts should monitor broader medical commodity codes and cooperative purchasing vehicle announcements rather than expect direct activity under this Commodity code.